Clinical Scorecard: The JinHuangJieDu (JHJD) formula reduces SARS-CoV-2 infection by disrupting RBD-ACE2 interaction and modulating HIF-1α-driven inflammation
At a Glance
Category
Detail
Condition
COVID-19
Key Mechanisms
Disruption of RBD-ACE2 interaction and modulation of HIF-1α-driven inflammation
Target Population
Patients with COVID-19, particularly those with severe symptoms
Care Setting
Traditional Chinese Medicine (TCM) practices
Key Highlights
JHJD effectively blocks SARS-CoV-2 RBD binding to ACE2.
Demonstrated efficacy against both wildtype and Omicron variants.
Targets HIF-1α to alleviate virus-induced inflammation.
Composed of six herbs with synergistic effects.
Promising therapeutic candidate for COVID-19 management.
Guideline-Based Recommendations
Diagnosis
Assess COVID-19 symptoms and confirm with PCR or rapid antigen tests.
Management
Consider JHJD as an adjunct therapy in COVID-19 treatment.
Monitoring & Follow-up
Monitor inflammatory markers and respiratory status in patients.
Risks
Potential for allergic reactions to herbal components.
Patient & Prescribing Data
Patients with symptomatic COVID-19, especially those at risk of severe disease.
JHJD may reduce symptom duration and severity when used alongside conventional therapies.
Clinical Best Practices
Integrate TCM with conventional medicine for enhanced efficacy.
Educate patients on the benefits and potential side effects of herbal treatments.
Monitor patient responses to JHJD and adjust treatment as necessary.
A global systematic review of 173 studies found differing associations between COVID-19 infection and vaccination and retinal vascular events, with retinal artery occlusion more common after infection and retinal vein occlusion more common after vaccination.
